Lab
Capital Health Laboratory LLC
Capital Health Laboratory LLC was paid $683K by Medicaid between Oct 2020 and Nov 2024, across 28 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 68% of everything it billed.
33Billing provider infoCAPITAL HEALTH LABORATORY LLC
KEYPORT, NJ 07735
KEYPORT, NJ 07735
33aNPI1841774429assigned 09/20/2018
33bProvider typeClinical Medical Laboratory
28Total paid$683K
24GClaims25,208
24DCodes billed28
24AFirst – last monthOct 2020 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New Jersey
Rank by total paid#70 of 122
Median peer was paid$1.29M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,897 | $108K | |
| 2021 | 8,617 | $328K | |
| 2022 | 4,280 | $158K | |
| 2023 | 6,556 | $59K | |
| 2024incomplete | 3,858 | $30K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 68% | 7,019 | 5,115 | $464K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 12% | 4,239 | 3,119 | $81K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 7.5% | 3,254 | 2,638 | $51K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 4.1% | 1,818 | 1,551 | $28K |
| 87631 | 2.0% | 1,137 | 1,008 | $14K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 799 | 768 | $8K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 124 | 109 | $6K |
| 87486 | <1% | 1,119 | 993 | $4K | |
| 87581 | <1% | 1,120 | 993 | $4K | |
| 87653 | <1% | 855 | 723 | $4K | |
| 87481 | <1% | 815 | 692 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 217 | 205 | $2K |
16 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 42 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 217 | $2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 369 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 163 | $1K |
| 87563 | <1% | 215 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 35 | $975.17 |
| 87541 | <1% | 187 | $912.00 | |
| 87641 | <1% | 220 | $840.35 | |
| 87500 | <1% | 186 | $812.28 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 110 | $296.28 |
| 87181 | <1% | 28 | $198.28 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 232 | $88.11 |
| 81003 | <1% | 530 | $82.86 | |
| 87076 | <1% | 28 | $46.31 | |
| 87640 | <1% | 89 | $43.86 | |
| 81001 | <1% | 41 | $24.11 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGURNANI, ARVIND (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Synergy Medical Laboratories INC | Keyport, NJ | $2.42M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.